News - TGFBR2 mutation

10ms

Genomic characteristics and prognosis of lung cancer patients with MSI-H: A cohort study. (PubMed, Lung Cancer)

The current study reveals the genetic characteristics of MSI-H lung cancer, which advanced our understanding of MSI-H lung cancer.

10 months ago

Journal • Tumor mutational burden • BRCA Biomarker • MSi-H Biomarker • PD(L)-1 Biomarker • IO biomarker

EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • BRCA2 (Breast cancer 2, early onset) • MSI (Microsatellite instability) • PTEN (Phosphatase and tensin homolog) • KMT2C (Lysine Methyltransferase 2C) • TGFBR2 (Transforming Growth Factor Beta Receptor 2)

PD-L1 expression • TP53 mutation • EGFR mutation • MSI-H/dMMR • PTEN mutation • TGFBR2 mutation

12ms

Effects of different immune microenvironment characteristics on effect of immune checkpoint inhibitors in solid tumors with TGFBR2 mutation. (ASCO 2023)

The results showed that the TGFBR2 had a high correlation in solid tumors with TMB and MSI. The TGFBR2 might a potential biomarker for ICIs therapy in NSCLC, and the immune microenvironment may be a factor affecting of it.

12 months ago

Checkpoint inhibition • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker

PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • PTCH1 (Patched 1) • CD4 (CD4 Molecule) • TGFBR2 (Transforming Growth Factor Beta Receptor 2) • TGFB1 (Transforming Growth Factor Beta 1)

PD-L1 expression • TMB-H • PTCH1 mutation • TGFBR2 mutation

PD-L1 IHC 22C3 pharmDx

12ms

Correlation between MSI, TMB, and TGFBR2 gene mutation in solid tumors. (ASCO 2023)

We analyzed the distribution of TGFBR2 mutants in Chinese patients with solid tumors. Our data showed that TGFBR2 mutant was significantly associated with TMB-H and MSI-H, and this may be a potential molecular marker of immunotherapy. And studies have shown that the combination of TGF-β inhibitors and immune checkpoint inhibitors can increase the killing effect of T cells on tumors.

12 months ago

Tumor mutational burden • MSi-H Biomarker • IO biomarker

TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • TGFBR2 (Transforming Growth Factor Beta Receptor 2) • TGFB1 (Transforming Growth Factor Beta 1)

TMB-H • MSI-H/dMMR • TGFBR2 mutation

over1year

SPARC expression in tumor microenvironment induces partial epithelial-to-mesenchymal transition of esophageal adenocarcinoma cells via cooperating with TGF-β signaling. (PubMed, Cell Biol Int)

Copresence of exogenous SPARC and TGF-β1 induced higher expression of mesenchymal markers and enhanced the invading capability of ESAD cells than TGF-β1 alone. In conclusion, this study suggests a potential cross-talk between ESAD tumor stromal cells and cancer cells via a SPARC-TGF-β1 paracrine network.

over 1 year ago

Journal

CDH1 (Cadherin 1) • SPARC (Secreted Protein Acidic And Cysteine Rich) • TGFBR2 (Transforming Growth Factor Beta Receptor 2) • VIM (Vimentin) • TGFB1 (Transforming Growth Factor Beta 1) • ZEB1 (Zinc Finger E-box Binding Homeobox 1)

CDH1 expression • TGFBR2 mutation • VIM expression • ZEB1 expression

2years

Genetically-engineered mouse model for colonic neoplasia presenting mucinous and microsatellite unstable phenotype (AACR 2022)

Mucin-producing adenocarcinomas develop in CDX2P9.5-G19Cre;Apcflox/+; Tgfbr2flox/flox mice. This GEMM is a potential mouse model recapitulating human mucinous and microsatellite unstable colorectal adenocarcinoma. The precise mechanism in which mucinous adenocarcinoma develops needs to be elucidated by genomic and transcriptomic analyses.

2 years ago

Preclinical • MSi-H Biomarker

MSI (Microsatellite instability) • TGFBR2 (Transforming Growth Factor Beta Receptor 2) • CDX2 (Caudal Type Homeobox 2)

MSI-H/dMMR • TGFBR2 mutation

over2years

TGFBR2 mutation predicts resistance to immune checkpoint inhibitors in patients with non-small cell lung cancer. (PubMed, Ther Adv Med Oncol)

We identified that TGFBR2 mutation predicted the resistance to ICIs in NSCLCs. The clinical delivery of ICIs should be cautious in those patients.

over 2 years ago

Clinical • Journal • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker

PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • PD-L2 (Programmed Cell Death 1 Ligand 2) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • TGFBR2 (Transforming Growth Factor Beta Receptor 2) • TGFB1 (Transforming Growth Factor Beta 1)

TGFBR2 mutation

almost3years

[VIRTUAL] Association of TGFBR2 mutations with shorter survival in non-small cell lung cancer treated with immune checkpoint inhibitors. (ASCO 2021)

TGFBR2 gene mutations are associated with shorter survival in NSCLC patients treated with ICIs, suggesting that TGFBR2 mutations be used as a potential biomarker of predicting the efficiency of immunotherapy and guiding NSCLC systemic treatment.

almost 3 years ago

Checkpoint inhibition • IO biomarker

TGFBR2 (Transforming Growth Factor Beta Receptor 2) • TGFB1 (Transforming Growth Factor Beta 1)

TGFBR2 mutation

almost3years

[VIRTUAL] Identification of TGFBR2 mutation as a negative predictor of immunotherapy in NSCLC. (ASCO 2021)

At last, we demonstrated a 39-year-old case with TGFBR2 mutation who was treated with 3 mg/kg nivolumab as second-line treatment... We identified TGFBR2 mutation as a negative predictor for ICIs in NSCLC and the clinical use of ICIs needs to be cautious in those patients, highlighting the importance of genomic profiling in the treatment of ICIs . Combination ICIs and TGF-β signaling inhibitors may overcome the resistance for those patients harboring TGFBR2 mutation and need to be developed in the future.

almost 3 years ago

PD(L)-1 Biomarker • IO biomarker

PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3) • PD-L2 (Programmed Cell Death 1 Ligand 2) • TGFBR2 (Transforming Growth Factor Beta Receptor 2)

TGFBR2 mutation

Opdivo (nivolumab)